TB-500 vs HGH 191AA

TB-500 and HGH 191AA represent two distinct classes of research peptides with divergent mechanisms and applications. TB-500, derived from the naturally occurring thymosin beta-4, is a short synthetic peptide (molecular weight ~889 g/mol) that promotes cell migration and tissue regeneration. In contrast, HGH 191AA is a full-length recombinant human growth hormone (molecular weight ~22,124 g/mol) identical to the pituitary-derived hormone, primarily studied for its anabolic and metabolic effects. Their differences extend to evidence levels: TB-500 is supported by a handful of human trials for wound healing and dry eye, while HGH 191AA has extensive clinical data and FDA approval for growth hormone deficiency. This comparison highlights their unique research profiles, including mechanisms, safety considerations, and shared applications in injury recovery and anti-aging studies.

TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found throughout human tissues. TB-500 contains the active healing region (sequence: Ac-LKKTETQ, MW ~889 g/mol) responsible for cell migration and tissue repair. It has a handful of human RCTs for wound healing and dry eye, plus a dedicated safety trial in 40 healthy adults showing minimal adverse effects. Despite this, it remains unapproved for human therapeutic use in all major markets and is banned by WADA and in horse racing.

Key claims: Accelerates wound healing; Reduces inflammation; Promotes cardiac repair.

HGH 191AA refers to recombinant human growth hormone (somatropin), a 191-amino-acid single-chain polypeptide (MW ~22,124 g/mol) identical in sequence to endogenous pituitary growth hormone. It is FDA-approved for growth hormone deficiency in children and adults, Turner syndrome, chronic renal insufficiency, Prader-Willi syndrome, and HIV-associated wasting. The designation '191AA' distinguishes it from the older 192-amino-acid variant (somatrem), which had an extra methionine residue and higher immunogenicity. Mechanistically, HGH 191AA binds to growth hormone receptors, stimulating insulin-like growth factor-1 (IGF-1) production and promoting anabolic effects on muscle, bone, and metabolism. Research suggests benefits in improving body composition in GH-deficient adults, with studies also exploring anti-aging and rejuvenation effects in healthy elderly populations, though these applications remain investigational.

TB-500 and HGH 191AA target distinct but occasionally overlapping research areas. TB-500 is primarily investigated for injury recovery and anti-inflammatory applications, with studies focusing on wound healing, tissue regeneration, and reducing fibrosis. In contrast, HGH 191AA is extensively studied for anti-aging and longevity, as well as body composition modulation, including muscle growth and fat metabolism. While both peptides have been explored in contexts of tissue repair and metabolic regulation, their mechanisms differ fundamentally: TB-500 acts via actin-binding and cell migration pathways, whereas HGH 191AA operates through endocrine signaling. Researchers may consider TB-500 for models of acute injury or inflammation, and HGH 191AA for chronic conditions involving growth hormone deficiency or age-related decline. Overlap exists in studies of cardiac repair and wound healing, but evidence is stronger for HGH 191AA in endocrine applications.

Safety profiles differ markedly between TB-500 and HGH 191AA. For TB-500, a safety-focused RCT in 40 healthy adults (2010) designed expressly to assess safety found minimal adverse effects with synthetic thymosin beta-4. No significant safety concerns have been reported in published human studies, with common anecdotal side effects including injection site pain or redness, lightheadedness, mild headache, nausea, and fatigue. In contrast, HGH 191AA has a well-documented safety profile from decades of clinical use. Common side effects include injection site reactions, fluid retention, joint pain or stiffness, and carpal tunnel syndrome. Metabolic effects such as insulin resistance and hyperglycemia (dose-dependent) may precipitate diabetes, while endocrine effects include gynecomastia and hypothyroidism (potentially unmasking central hypothyroidism). Researchers should consider these differences when designing studies, particularly regarding long-term metabolic monitoring for HGH 191AA.